Community Practice Connections: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes
This activity is supported by Regeneron Pharmaceuticals, Inc.
Overview
Release Date
December 9, 2024
Expiration Date
December 9, 2025
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by Regeneron Pharmaceuticals, Inc.
Activity Overview
Retinal diseases including neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), and diabetic macular edema (DME) are significant causes of vision loss and blindness. Newer anti-VEGF therapies that allow extended intervals between injections may reduce treatment burden for patients with these conditions.
This Community Practice ConnectionsTM program provides an in-depth review of some of the key highlights of the Modern-izing Retina conference, held in September 2024. This unique and engaging multimedia activity is ideal for the community-based eye care professional and focuses on the practical aspects of treating nAMD, DME, and DR. The program is designed for those who did not attend the virtual conference and to help reinforce learnings for those who did.
Target Audience
This educational activity is directed toward retinal specialists.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify appropriate patient populations who may benefit from evidence-based therapies used in the management of nAMD based on clinical presentation and goals of treatment
- Evaluate the potential impact of new anti-VEGF agents in the treatment of nAMD
- Identify prevalent challenges in patient adherence to diabetic eye disease management
- Integrate recently approved targeted therapies for the management of DME and DR in appropriate patients
Faculty
David A. Eichenbaum, MD
Director, Research
Retina Vitreous Associates of Florida
Collaborative Associate Professor of Ophthalmology
Morsani College of Medicine
University of South Florida
Clearwater, FL
Disclosures: Grant/Research Support: 4DMT Molecular Therapeutics, Alexion, Allgenesis Biotherapeutics, Annexon, Aviceda Therapeutics, Bayer, EyePoint Pharmaceuticals, Gemini, Gyroscope Therapeutics, Ionis Pharmaceuticals, IVERIC bio, Janssen, Kodiak Sciences, Mylan, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, ONL Therapeutics, Opthea, RecensMedical, Regeneron Pharmaceuticals, REGENXBIO, Unity; Consultant: Alimera Sciences, Allergan, Annexon, Apellis Pharmaceuticals, Bausch + Lomb, Coherus BioSciences, Crinetics Pharmaceuticals, EyePoint Pharmaceuticals, Genentech, IVERIC bio, Kodiak Sciences, Ocular Therapeutix, Opthea, Outlook Therapeutics, RecensMedical, Regeneron Pharmaceuticals, REGENXBIO, ReVive, Samsara;
Speakers Bureau: Allergan, Apellis Pharmaceuticals, Genentech, IVERIC bio, Regeneron Pharmaceuticals. Shareholder: Boston Image Reading Center, Janssen, Network Eye, USRetina.
Roger A. Goldberg, MD, MBA
Vitreoretinal Specialist
Partner, Bay Area Retina Associates, Walnut Creek, CA
Faculty, CPMC Ophthalmology, San Francisco, CA
Disclosures: Research Grants: AffaMed, Allergan, Annexon, Apellis, Boehringer Ingelheim, EyePoint, Genentech, Janssen, Neurotech, Novo Nordisk, Unity, ZEISS; Consultant: Allergan, Annexon, Apellis, Boehringer Ingelheim, Biogen, Coherus, EyePoint, Genentech, IrisVision, Ocular Therapeutix, Outlook, Regeneron, ZEISS; Speaker: Apellis, Biogen, Genentech; Stock Owner: Emmetrope Ophthalmics.
Priya Vakharia, MD
Retina Vitreous Associates of Florida
Tampa, FL
Disclosures: Speakers Bureau: Apellis, Astellas, Bausch + Lomb, Genentech, Heidelberg, Regeneron; Consultant: Alimera, Apellis, Astellas, Bausch + Lomb, Bayer, Coherus, EyePoint, Genentech, Heidelberg, Notal Vision, Novartis, Ocuphire, Quad-C/PRISM, Regeneron; Investigator: 4DMT, Alexion, Allgenesis, Annexon, Aviceda, Ionis, Janssen, Kodiak, Ocular Therapeutics, OcuTerra, ONL Therapeutics, Opthea, Regenxbio, Unity.
Geeta Lalwani, MD
Board Certified Ophthalmologist
Founder of Rocky Mountain Retina Associates
Medical and Surgical Vitreoretinal Specialist
Boulder, CO
Disclosures: Consultant: Apellis, Genentech, Iveric Bio, Regeneron; Other: Ownership Interests: Ocugen.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.